The largest database of trusted experimental protocols

Transfers, Embryo

Embryo Transfers refers to the process of transferring one or more embryos into the uterus of a female, typically during in vitro fertilization (IVF) procedures.
This technique aims to establish a successful pregnancy by placing the embryo(s) in the optimal location for implantation.
Factors such as embryo quality, timing of transfer, and transfer technique can influence the outcome of Embryo Transfers.
Researchers and clinicians utilize PubCompare.ai's AI-driven protocol comparisons to optimize this critical step in the IVF process, improving reproducibility and research accuracy.
The intelligent tool helps locate the best protocols from literature, pre-prints, and patents, allowing users to discover the ideal protocols and products for their Embryo Transfer needs and enhance the chances of a successful pregnancy.

Most cited protocols related to «Transfers, Embryo»

Embryo collection was performed in a surgical room located on the farm. The donors were subjected to a midventral laparotomy on Days 5 and 6 of the estrous cycle (Day 0: onset of estrus) to obtain morulae and unhatched blastocysts, respectively. The donors were sedated by the administration of azaperone (2 mg/kg body weight, intramuscular). General anesthesia was induced using sodium thiopental (7 mg/kg body weight, intravenous) and maintained with isoflurane (3.5–5%). After exposure of the genital tract, the corpora lutea on the ovaries were counted. Embryos were collected by flushing the tip of each uterine horn with 30 mL of a chemically defined medium consisting of Tyrode's lactate (TL)-HEPES-polyvinyl alcohol (PVA) [17] (link) with some modifications. This medium (TL-PVA) was composed of 124.3 mM NaCl, 3.2 mM KCl, 2 mM NaHCO3, 0.34 mM KH2PO4, 10 mM Na-lactate, 0.5 mM MgCl2·6H2O, 2 mM CaCl2·2H2O, 10 mM HEPES, 0.2 mM Na-pyruvate, 12 mM sorbitol, 0.1% (w/v) PVA, 75 µg/ml potassium penicillin G and 50 µg/mL streptomycin sulfate. The collected embryos were evaluated to verify their developmental stage and quality grade. One-cell eggs and poorly developed embryos were classified as oocytes and degenerate embryos, respectively. The remaining embryos that exhibited appropriate morphology according to the criteria determined by the International Embryo Transfer Society [18] were considered viable. Only compacted morulae and unhatched blastocysts graded as excellent or good based on morphological appearance were used in the experiments according to the specific experimental design.
The ovulatory response of the donors was determined by counting the number of corpora lutea in both ovaries. To evaluate the effectiveness of the superovulation treatment, the numbers of viable embryos and oocytes and degenerate embryos were counted in each donor. The recovery rate was defined as the ratio of the number of embryos and oocytes and degenerate embryos recovered to the number of corpora lutea present. The fertilization rate was defined as the ratio of the number of viable embryos to the total number of embryos and oocytes and degenerate embryos collected.
Full text: Click here
Publication 2014
Azaperone Bicarbonate, Sodium Blastocyst Body Weight Cells Corpus Luteum Donors Eggs Embryo Estrous Cycle Estrus Fertilization General Anesthesia Genitalia HEPES Isoflurane Lactates Laparotomy Magnesium Chloride Morula Operative Surgical Procedures Ovary Ovulation Ovum Penicillin G Potassium Polyvinyl Alcohol Pyruvate Sodium Chloride Sorbitol Streptomycin Sulfate Thiopental Sodium Tissue Donors Transfers, Embryo Uterine Cornua
All animal procedures were carried out in accordance with UK legal requirements and in under licensed approval from the UK Home Office. In the current study a mouse model of menstruation described by Brasted et al [15] (link) was modified to include non-surgical induction of decidualisation and a longer decidualisation period. Uterine tissues were also collected during a period of active shedding and repair, time-points that have not been previously described.
On day 0, C57BL/6J mice between 8–10 weeks of age were ovariectomised to deplete endogenous steroid production. Mice received daily injections of β-oestradiol (E2) in sesame seed oil (100 ng/100 µl, days 7–9). A progesterone (P4)-secreting pellet was placed sub-cutaneously on day 13; mice also received daily injections of sub-cutaneous injections of E2 (5 ng/100 µl, days 13–15). On day 15, decidualisation of one uterine horn was induced by stimulation of the horn using sesame seed oil (20 µl) inserted into the uterine lumen via the cervix using a non-surgical embryo transfer device (NSET) from Datesand Ltd. (Manchester, UK). The contra-lateral horn acted as a control. P4 withdrawal was induced 90 hours after decidualisation by removing the P4-pellet. Mice were culled by asphyxiation and cervical dislocation at time of P4 withdrawal or 4, 8, 12, 24 and 48 hours thereafter (Figure 1). Mice received an intra-peritoneal injection of bromodeoxyuridine (BrdU, 2.5 mg/ml) 90 minutes prior to culling to detect cellular proliferation. Blood sera were collected, uteri dissected and collected into RNA later or 4% neutral buffered formalin. Any mouse in which the oil-treated horn had not decidualised was excluded from the study.
Full text: Click here
Publication 2014
5-bromouridine Animals Asphyxia Bromodeoxyuridine Cervix Uteri Decidual Cell Reaction Estradiol Formalin Horns Hyperplasia Injections, Intraperitoneal Joint Dislocations Medical Devices Menstruation Mice, Inbred C57BL Mus Neck Operative Surgical Procedures Progesterone Serum Sesame Oil Skin Steroids Tissues Transfers, Embryo Uterine Cornua Uterus

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Actins Alleles Animals Animals, Transgenic Branchial Arch Buffers Cloning Vectors Embryo Forehead Genes Genome Institutional Animal Care and Use Committees LacZ Genes Mice, Laboratory Mice, Transgenic noggin protein Open Reading Frames paraform Polymerase Chain Reaction Tail Transfers, Embryo Transgenes Unverricht-Lundborg Syndrome WNT1 protein, human
The collection of embryos was performed in a specifically designed surgical room located on the farm. The donors were subjected to a mid-ventral laparotomy on Day 6 of the estrous cycle (Day 0: onset of estrus). The donors were sedated with azaperone (2 mg/kg body weight, intramuscular). General anesthesia was induced using sodium thiopental (7 mg/kg body weight, intravenous) and was maintained with isoflurane (3.5-5%). After exposure of the genital tract, the corpora lutea on the ovaries were counted. The embryos were collected by flushing the tip of each uterine horn with 30 mL of Tyrode’s lactate (TL)-HEPES-polyvinyl alcohol (PVA)15 (link) with some modifications4 . The recovered embryos were evaluated under a stereomicroscope at a magnification of 60× to grade the developmental stage and quality. One-cell eggs and poorly developed embryos were classified as unfertilized oocytes and degenerated embryos, respectively. The remaining embryos with the appropriate morphology according to the criteria determined by the International Embryo Transfer Society16 were considered viable. Vitrification was only performed on compacted morulae and unhatched blastocysts with morphology graded as excellent or good.
The ovulatory response of the donors was determined by counting the number of corpora lutea on both ovaries. Recovery rate was defined as the ratio of the number of embryos and oocytes and degenerated embryos recovered to the number of corpora lutea present. Fertilization rate was defined as the ratio of the number of viable embryos at collection to the total number of embryos and oocytes and degenerated embryos collected.
Full text: Click here
Publication 2015
Azaperone Blastocyst Body Weight Cells Corpus Luteum Donors Eggs Embryo Estrous Cycle Estrus Fertilization General Anesthesia Genitalia HEPES Isoflurane Lactates Laparotomy Morula Operative Surgical Procedures Ovary Ovulation Ovum Polyvinyl Alcohol Thiopental Sodium Transfers, Embryo Uterine Cornua Vitrification

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Atmosphere Bos taurus Brief Treatment Cell Nucleus Cells Culture Media Cytochalasin B cytochalasin H Embryo HEPES Hyaluronidase Microinjections Oocytes Preimplantation Embryo Development RNA, Messenger Sertoli Cells Student Tissue Donors Transfers, Embryo trichostatin A Viral Envelope Woman

Most recents protocols related to «Transfers, Embryo»

We input “recurrent implantation failure” and “expression profile” as two keywords to the GEO database, then two datasets GSE103465 and GSE111974 were selected for analysis, and GSE26787 was chosen for validation. Both GSE103465 and GSE111974 contain expression profiles of endometrial tissue obtained from RIF and control women during WOI. GSE103465, in GPL16043 platform, contains whole-genome expression profiles of endometrial tissue from three women divided to the control group and RIF group (Guo et al., 2018 (link)). In GSE103465, RIF is defined as no pregnancy after ≥3 embryo transfers including a total of ≥4 good-quality embryos, and inclusion criteria of control group is infertile women with tubal factors who achieved a clinical pregnancy after the first embryo transfer (Guo et al., 2018 (link)). GSE111974, in GPL17077 platform, consists of 24 individuals with RIF and 24 fertile control patients, in which RIF is determined as failure of pregnancy in three consecutive IVF cycles with at least one transfer of good quality embryo in each cycle, while the fertile control refers to patients who had a history of at least one live birth with no related comorbidities (Bastu et al., 2019 (link)). The platform and series matrix files were all downloaded.
Full text: Click here
Publication 2023
Contraceptive Methods Embryo Endometrium Female Infertility Genetic Profile Ovum Implantation Patients Pregnancy Tissues Transfers, Embryo Woman
Controlled ovarian hyper-stimulation was performed using a short-acting GnRH agonist long protocol. Recombinant follicle-stimulating hormone (Merck Serono) was started at least 14 days after the downregulation of GnRH agonist for complete suppression of estradiol from 75 to 300IU/d. Ovulation was induced with human chorionic gonadotropin, and approximately 36 hours later, oocyte retrieval was performed under transvaginal ultrasonographic guidance. Fertilization was carried out using the standard IVF technique; if male infertility or fertilization failure occurred, oocytes were inseminated by ICSI. Embryo transfer was mostly performed using cleaving stage embryos (day 3). If a patient was at risk of ovarian hyperstimulation syndrome, the embryo was vitrified and transferred to a subsequent substituted cycle.
Publication 2023
Down-Regulation Embryo Estradiol Fertilization Gonadorelin Human Chorionic Gonadotropin Human Follicle Stimulating Hormone Male Infertility Oocyte Retrieval Ovarian Hyperstimulation Syndrome Ovarian Stimulation Ovulation Ovum Patients Sperm Injections, Intracytoplasmic Transfers, Embryo
We retrospectively collected information from 273 patients who underwent IVF/ICSI with fresh embryo transfer following an endometrial curettage in the proliferative-phase from January 2020 to May 2022 in the Reproductive Hospital of Jiangxi University of Traditional Chinese Medicine. These patients had no or only 1 previously failed cycle. Patients with uterine abnormalities, endometriosis, intrauterine adhesions (moderate-severe), adenomyosis, uterine mediastina and ovarian tumors, untreated hydrosalpinx, or abnormal uterine bleeding were excluded. All data of patients on demographics, baseline values, and pregnancy outcomes were available. We obtained ethical approval from the Medical Ethics Committee of Nanchang Reproductive Hospital (the Reproductive Hospital of Jiangxi University of Traditional Chinese Medicine) (approval number 2022.005).
Publication 2023
Adenomyosis Curettage Endometriosis Endometrium Ethics Committees, Clinical Mediastinum Menstrual Cycle, Proliferative Phase Ovarian Neoplasm Patients Reproduction Sperm Injections, Intracytoplasmic Tissue Adhesions Transfers, Embryo Uterine Anomalies Uterus
The process of IVF or ICSI was conducted according to the standard protocols of our study centers. We performed different types of controlled ovarian hyperstimulation (COH) protocols (gonadotropin-releasing hormone (GnRH)-agonist protocol, GnRH-antagonist protocol, micro-flare protocol or others) according to the state of each patient (age, ovarian reserve and others). After COH, when the leading follicle reached 20mm in diameter or at least two follicles reached 18 mm, ovulation was induced by giving human chorionic gonadotropin (HCG) or gonadotropin-releasing hormone agonists (GnRH-a). Oocyte retrieval was performed 34-38 hours later and oocytes were fertilized by either conventional IVF or intracytoplasmic sperm injection after the assessment of semen quality. Subsequently, viable embryos were transferred in fresh embryo transfer cycles or frozen-thawed embryo transfer (FET) cycles after oocyte retrieval and routine corpus luteum support was performed after transplantation if conceived.
Full text: Click here
Publication 2023
agonists Corpus Luteum Embryo Freezing Gonadorelin Hair Follicle Human Chorionic Gonadotropin Oocyte Retrieval Oocytes Ovarian Follicle Ovarian Reserve Ovulation Ovulation Induction Patients Semen Quality Sperm Injections, Intracytoplasmic Transfers, Embryo Transplantation
This retrospective, multi-center cohort study was conducted on women who underwent IVF/ICSI cycles and achieved live births from January 2014 to October 2019 in three study centers among different provinces in China, including International Peace Maternity and Child Health Hospital (Shanghai), Ningbo Women and Children’s Hospital (Zhejiang Province), Suzhou Municipal Hospital (Jiangsu Province). The study was approved by the research ethics board of each center and written informed consent forms (ICFs) were obtained from all the participants before inclusion.
Subjects were identified from the database in three centers from January 2014 to October 2019 using the following inclusion and exclusion criteria. The inclusion criteria were set as follows: 1) female participants aged between 20 and 45 years, 2) participants with serum AMH measurement within 12 months before undergoing IVF/ICSI cycles. The participants were excluded if they met the following criteria: 1) participants who underwent pre-implantation genetic testing (PGT), 2) participants using donor semen or donor oocyte, 3) mixed transfers with embryos retrieved from different oocyte retrieval cycles, 4) women with severe chronic diseases, 5) women for whom main data were missing or who were lost to follow-up. The participants were categorized into three groups according to the <25th(low), 25th to 75th(average), and >75th(high) percentile of serum AMH concentration (0.01-1.76, 1.76-5.41, 5.41-25.00ng/ml). The subgroup analysis was conducted based on the number of live births.
Full text: Click here
Publication 2023
Children's Health Disease, Chronic Females Oocyte Retrieval Oocytes Ovum Implantation Plant Embryos Serum Sperm Injections, Intracytoplasmic Tissue Donors Transfers, Embryo Woman

Top products related to «Transfers, Embryo»

Sourced in Germany, France, China, Belgium
Progynova is a laboratory equipment product manufactured by Bayer. It is a device used for the analysis and measurement of progesterone levels in biological samples. The core function of Progynova is to provide accurate and reliable results for progesterone testing in research and clinical settings.
Sourced in Switzerland, Germany, Italy, France, United States, Spain, Netherlands, United Kingdom, Australia, Japan, Denmark, Brazil, China
Gonal-F is a recombinant human follicle-stimulating hormone (r-hFSH) produced by recombinant DNA technology. It is used as a fertility medication to stimulate follicular development and maturation in the ovary as part of an assisted reproductive technology (ART) program.
Sourced in United Kingdom, Switzerland, Germany
Crinone is a medical device produced by Merck Group that is used for the administration of progesterone in gel form. It is designed to provide a controlled release of progesterone to support early pregnancy in certain medical conditions.
Sourced in Switzerland, Germany, Italy, United States, Brazil, Australia
Ovidrel is a laboratory product manufactured by Merck Group. It is a recombinant human chorionic gonadotropin (hCG) medication used for in vitro fertilization (IVF) procedures. Ovidrel is designed to trigger the final stage of egg maturation prior to ovulation.
Sourced in United States, Netherlands
Duphaston is a pharmaceutical product manufactured by Abbott. It is a synthetic progestogen used as a hormonal supplement.
Sourced in Switzerland, United Kingdom, Israel
Crinone 8 is a progesterone-containing vaginal gel product manufactured by Merck Group. It is designed for use in assisted reproductive technology (ART) procedures.
Sourced in Switzerland, Germany, United States, Denmark, Canada, Belgium, Spain, China, France, Sweden, United Kingdom
Menopur is a medication used in assisted reproductive technology (ART) procedures. It contains a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are hormones that play a crucial role in the development and maturation of ovarian follicles.
Sourced in Germany, Switzerland, France, Italy, United Kingdom, Netherlands
Ovitrelle is a laboratory product manufactured by Merck Group. It is a gonadotropin-releasing hormone agonist used in in-vitro fertilization procedures.
Sourced in United States, Netherlands
Dydrogesterone is a synthetic progestogen compound that is used in laboratory research and testing. It is a chemical substance that acts similarly to the natural hormone progesterone, which is involved in the regulation of the menstrual cycle and pregnancy.
Sourced in Japan
The Cryotop is a lab equipment product developed by Kitazato for cryopreservation. It is a device used to vitrify and store biological samples, such as cells or embryos, at ultra-low temperatures.

More about "Transfers, Embryo"

Embryo Transfers refer to the process of placing one or more embryos into a woman's uterus, typically during in vitro fertilization (IVF) procedures.
This crucial step aims to establish a successful pregnancy by positioning the embryo(s) in the optimal location for implantation.
Factors such as embryo quality, timing of transfer, and transfer technique can influence the outcome of Embryo Transfers.
Researchers and clinicians utilize advanced tools like PubCompare.ai's AI-driven protocol comparisons to optimize this critical stage in the IVF process, improving reproducibility and research accuracy.
This intelligent tool helps locate the best protocols from a wealth of literature, pre-prints, and patents, allowing users to discover the ideal protocols and products for their Embryo Transfer needs and enhance the chances of a successful pregnancy.
In the context of Embryo Transfers, it's important to consider related fertility medications and treatments, such as Progynova, Gonal-F, Crinone, Ovidrel, Duphaston, Crinone 8, Menopur, Ovitrelle, and Dydrogesterone.
These products can play a crucial role in supporting the IVF process, from ovarian stimulation to luteal phase support.
By understanding the synergies between Embryo Transfers and these complementary treatments, clinicians can develop comprehensive strategies to maximize the chances of a successful outcome for their patients.